We are pleased with the continued positive clinical progress across our companies over the period, with five clinical stage businesses now within the Syncona portfolio
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today issues its quarterly update covering the period from 31 March 2021 to 30 June 2021.
Key operational and financial highlights:
- Strong clinical progress with five clinical stage companies now in the portfolio, following Anaveon dosing its first patient in June
- Freeline Therapeutics doses further patient in its second clinical programme in Fabry disease
- Autolus Therapeutics published further encouraging durability data in its AUTO1 programme for adult acute lymphoblastic leukaemia (ALL)
- Net assets of £1,200.4 million, 178.9p per share, a NAV return of (7.7) per cent in the period
- Life science portfolio valued at £622.4 million (31 March 2021: £722.1 million), a total return of (13.9) per cent in the quarter
- Listed portfolio companies are funded to deliver further clinical data, which is the key driver of value; share prices of the listed holdings have been volatile but Syncona is focused on the long term and remains confident in the companies’ fundamentals and recent progress
- Capital base of £578.0 million on 30 June 2021
- New members of expanded senior leadership team are now operational, with Rolf Soderstrom (Chief Financial Officer), Fiona Langton-Smith (Chief Human Resources Officer) and Markus John (Head of R&D and Chief Medical Officer) joining the business
Martin Murphy, CEO, Syncona Investment Management Limited, said: “We are pleased with the continued positive clinical progress across our companies over the period with Anaveon dosing the first patient in its clinical programme and becoming Syncona’s fifth clinical-stage business.
Whilst we recognise that the share price performance of our listed holdings has brought volatility to our NAV, we remain focused on delivering value over the long-term. Our portfolio is funded to deliver important clinical milestones, which are potential key value drivers for our business over the next 12-24 months. Our companies are executing on their business and clinical plans and we have a high level of conviction in their fundamentals. We also continue to seek a wide range of exciting new opportunities to found and invest in the next generation of globally leading life science businesses.”
 Fully diluted